Includes information on upcoming and past events organised by the Irish Pharmaceutical Healthcare Association (IPHA).

The Digital ThinkIn Series – a new initiative by IPHA – will profile some of the latest thinking about themes shaping the originator biopharmaceutical industry in Ireland and around the world. Over the autumn-winter period, we will run with partners a slate of virtual events which we hope you will find informative and engaging. We are delighted that Uniphar is our sponsor. Over many years, Uniphar has sponsored our annual conference. Unfortunately, this year we are unable to run an annual conference due to COVID-19 restrictions. Instead, we are bringing you the latest thinking from some of our partners through a series of virtual events.

The series will explore a range of themes – from innovative contracting in cell and gene therapy to the social determinants of better health; from digital healthcare to changing behaviours in self-care; and from the value of medicines to the latest trends in medicines reimbursement.

We are grateful to EY, Deloitte, PwC, WifOR, IQVIA and Behaviour & Attitudes for partnering with us on the Digital ThinkIn Series.

Funding Innovative New Medicines

How is Ireland faring in a European context when it comes to speed of access to innovative new medicines and the amount of public funding available to pay for them? With the severe economic shock caused by COVID-19, what is the outlook for the reimbursements of new medicines? What does the horizon scan tell us about the new medicines in the pipeline?

We were delighted to explore these questions in partnership with health data analysts IQVIA. You can view the contributions by Lisa Taylor, VP Consulting EMEA Real-World Access, IQVIA; Sarah Rickwood, VP Thought-Leadership EMEA, IQVIA; and Gwynne Morley, General Manager, IQVIA (Ireland) here.


 Could Innovative Contracting Accelerate Access To CGTs?

Cell and gene therapies (CGTs) are among the most exciting developments in the biopharmaceutical industry globally. These advanced treatments will need to reflect breakthrough science driving better patient outcomes, as well as a good deal for payers. With healthcare resources even more stretched than before, industry and payers will need to examine and adopt new reimbursement models that demonstrate that the therapies are worth their high prices.

In partnership with EY, we explored emerging trends, contracting models and future considerations for CGT reimbursement in Ireland. You can view the contributions by Alice Blezat, Innovative Contracting Lead, EY UK; Gary Comiskey, Director, Government and Health, EY Ireland; Gilles Ducorroy, Head, Real-World Evidence Services, Novartis; and Dr Larry Bacon, Consultant Haematologist, St James’s Hospital, Dublin here.

Self-Care And Changing Behaviours In The Next Normal

COVID-19 has transformed how we live and how we work. Our routines have been turned upside down. Our physical and mental wellbeing is in the spotlight. So, how are we coping? This session explores how COVID-19 has fundamentally changed our behaviour – from how people use community pharmacies to how they can best mind their own health; from the food we eat and the sleep we get; from the exercise we take to the way we shop; from how we communicate with family and friends to the experience of working remotely.

We hear new insights from polling experts about how behaviours have changed during the pandemic. We ask whether the experience of dealing with the pandemic will yield permanent changes, for better or worse, in how we care for ourselves.

We explore these new trends and themes in partnership with pollsters Behaviour & Attitudes.

This event is run jointly by IPHA and IPU.

Time: 8am to 9.30am 

Date: October 6, 2020

Register now


The Value of Medicines Innovation For Society

Medicines innovation creates value for society. New medicines are credited with improving health outcomes. That means people are living longer, healthier lives, with better overall wellbeing and mental health. People are more productive if their health is better so they can contribute to the economy. As well as better treating diseases, medicines are preventing more of them. All this has implications for human capital and for economies – adding healthy life years to populations, boosting productivity and avoiding costs by reducing the burden of disease.

We examine how medicines innovation benefits societies and economies, with a focus on Ireland and Germany. We explore the therapeutic value of medicines in Ireland in areas like cancer and cardiovascular disease, with new insights on how interventions have prolonged life expectancy and kept people active in society. We hear from health and policy and clinical leaders in Germany whose experience with medicines innovation has helped to reset the trajectory of disease. We explain the link between health and opportunity and try to show how medicines innovation is an investment rather than a cost.

We explore all this in partnership with economic research institute and think tank WifOR.

Time: 8am to 9.30am 

Date: October 27, 2020


The Social Determinants of Health

Bold action is needed to rethink how all players in the healthcare ecosystem can work together to treat diseases – and to address their causes. Medicines innovation is adding time and quality to people’s lives. The social determinants of health – often-ignored social factors such as employment, housing, income inequality, and level of access to clean water, education and transport – can undermine progress in raising health outcomes. Governments, in Ireland and around the world, should not ignore these factors.

We examine how social factors can often counteract medical best practice. When health systems implement solutions for people already sick and in crisis, it may be too late. The point of intervention should come before then – and sometimes the best preventative pathways are social rather than therapeutic.

We hear what it takes to build collective will in confronting the social determinants of health. Stakeholders spanning the health ecosystem – policymakers, biopharmaceutical companies, doctors, patients and others – are, in many countries, a loose coalition whose collective focus is often not on creating the social conditions for better health. We ask how that can be improved – for Ireland and for the world.

We explore these themes in partnership with consulting firm PwC.

 Time: 8am to 9.30am 

Date: November 5, 2020


Driving A New Future For Healthcare

Data is taking centre stage in the future of global healthcare. No longer passive observers, payers are instead demanding more detailed evidence about the performance of medicines. This shift to a fundamentally patient-centric approach will require the market to adapt to the needs of the ‘empowered consumer’.

So, where is all this leading? What does it mean for healthcare and for medicines development – for patient outcomes and for adoption by health services? The future of healthcare will be driven by radically interoperable data, with open platforms connecting individual, population and environmental datasets in real time. That will allow us to leverage previously untapped or unknown data and arrive at new, revolutionary insights.

We explore these trends in partnership with consulting firm Deloitte.

Time: 8am to 9.30am

Date: November 12, 2020